

RESEARCH

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy

Shaomin Shi¹, Xinghua Chen², Wen Yu³, Xiaolan Ke¹ and Tean Ma¹¹Division of Nephrology, The First Affiliated Hospital of Yangtze University, Jingzhou, China²Division of Nephrology, Renmin Hospital of Wuhan University, Wuhan, China³Department of Immunology, School of Medicine, Yangtze University, Jingzhou, ChinaCorrespondence should be addressed to T Ma: matean@yangtzeu.edu.cn

Abstract

Protection of podocytes is one of the important means to delay the progression of diabetic nephropathy (DN), and glucagon-like peptide-1 (GLP-1) has been shown to have a protective effect on the kidney in DN models, but whether it has a protective effect on podocytes and the potential mechanisms of action remain largely unknown. In the present study, we established a type 2 diabetes mellitus (T2DM) mouse model by high-fat diet feeding combined with streptozotocin (STZ) induction and administered the intervention for 14 weeks. We found that liraglutide significantly ameliorated podocyte injury in DN mice. Mechanistically, we detected glucagon-like peptide-1 receptor (GLP-1R) protein expression levels in kidney tissues by immunohistochemical staining, immunofluorescence staining, and western blotting and found that podocytes could express GLP-1R and liraglutide treatment could restore GLP-1R expression in the kidney tissues of DN mice. Furthermore, we found that NLRP3-induced inflammation and pyroptosis were positively correlated with podocyte injury in DN mice, and liraglutide inhibited the expression of NLRP3-induced inflammation and pyroptosis-related proteins. Our results suggest that liraglutide protects DN mouse podocytes by regulating GLP-1R in renal tissues and by regulating NLRP3-induced inflammation and pyroptosis.

Key Words

- ▶ liraglutide
- ▶ diabetic nephropathy
- ▶ podocytes
- ▶ glucagon-like peptide-1 receptor
- ▶ pyroptosis

Endocrine Connections
(2023) 12, e230284

Introduction

Diabetic nephropathy (DN) is one of the microvascular complications of diabetes, and according to the International Diabetes Federation, the number of people with diabetes is expected to exceed 780 million by 2045 (1). Diabetic nephropathy has become the leading cause of chronic kidney disease and end-stage renal disease (ESRD) worldwide in recent years, and with its high mortality rate, it is a major burden on health care worldwide (2). The classical albuminuric phenotype of diabetic nephropathy (DN) is mainly due to damage to glomerular podocytes (3). Podocytes, the highly specialized glomerular epithelial cells, form the glomerular basement membrane (GFB) together with the fenestrated endothelium and the glomerular basement membrane (3, 4, 5). Podocyte injury is an early event

in the development of DN (6), and the loss and fusion of podocytes can be observed in the early stages of DN (7). Podocytes have a limited proliferative capacity, and the loss of more than 20% of podocytes represents an irreversible alteration in DN pathogenesis, leading to glomerular scar formation and ESRD progression (8, 9). In-depth investigation of the damage process of podocytes and protection of podocytes are important tools for the treatment of glomerular diseases and key targets for the prevention and treatment of glomerular diseases (10, 11).

Glucagon-like peptide-1 (GLP-1) is an endogenous entero-insulinotropic hormone whose main target of action is GLP-1 receptor (GLP-1R). GLP-1R is expressed in islet β -cells and several extrapancreatic tissues,

including the small inlet arteries, proximal tubules, and collecting ducts of the kidney (12, 13). GLP-1R activity is significantly reduced in chronic kidney disease (14), and several studies have shown that GLP-1 has a protective effect on the kidney (15, 16, 17).

The mechanism of renal protection by GLP-1 analogs is not well understood. To further investigate the protective effect of liraglutide on podocytes in T2DM nephropathy in addition to its hypoglycemic effect, this study was conducted to establish a T2DM mouse model using a high-fat diet (HFD) combined with streptozotocin (STZ) induction and to investigate the protective effect of liraglutide on podocytes and its related molecular mechanism by detecting the differences in the expression levels of specific proteins and the pathological changes in the kidneys of these model mice. It is expected to provide a more theoretical basis for preventing the occurrence of albuminuria, delaying the progression of renal injury in T2DM patients, and providing a more theoretical basis for the rational clinical application of these drugs.

Materials and methods

Animals and group treatment

We purchased male-specific pathogen-free (SPF) C57BL/6J mice, aged 8 weeks, weighing 22–28 g from the Experimental Animal Center of Beijing Weitong Company and raised them in SPF conditions (Animal Quality Certificate No.: SCXK (Beijing) 2021-0006). These mice were alternately exposed to 45–55% humidity and light and darkness for 12 h in turn at a temperature of 18–22°C, with adequate food and water intake. All experiments performed were approved by the Ethical Committee of Experimental Animal Care of Yangtze University. The code is No.202301005.

After 1 week of adaptive feeding on a normal diet, 32 C57BL/6J male mice were divided into a normal diet group (14% fat) (NC, $n=8$) and a HFD group (60% fat) (HFD, $n=24$) using a simple random sampling method. After 4 weeks of different feedings, six mice in each group were randomly selected for glucose tolerance test. The mice were fasted but given adequate water for 12 h, glucose at a concentration of 20% (2 g/kg) was injected intraperitoneally, blood was taken from the tail vein, and blood glucose was measured by a glucometer at the corresponding time points of 0 min, 15 min, 30 min, 60 min, and 120 min. Then the HFD group was given a 1% STZ (S0130, Sigma) intraperitoneal injection (for 5 days

of continuous administration, 50 mg/kg day dissolved in 0.1 M citrate buffer, pH 4.5). The NC group was injected with an equal amount of citrate buffer. After 7 days, the HFD group mice showed the symptoms of diabetes as polyuria, polydipsia, polyphagia, and weight loss, and the random blood glucose (GLU) levels were measured over 16.7 mmol/L by a blood glucose meter (Accu-Chek, Roche) for 2 consecutive days, which was considered T2DM mice (18). These T2DM mice were divided into the T2DM nephropathy model group (DN group, $n=8$), liraglutide treatment group (DN+Lira group, $n=8$) (Novo Nordisk, 400 µg/kg day, subcutaneous injection), and degludec insulin treatment group (DN+RI group, $n=8$) (Novo Nordisk, 1–2 U/kg day, subcutaneous injection). The dosage of degludec insulin was adjusted according to the level of GLU. The NC and DN groups received daily subcutaneous injections of an equal volume of saline. All injections were completed at 18:00–19:00 daily.

24-h urinary protein determination and biochemical parameters

Tail-tip blood was collected regularly every week for GLU measurements in each group. At 8 weeks and 14 weeks after administration, each mouse was placed in a metabolic cage to collect 24-h urine for urinary protein quantification according to the method of the urinary protein test kit (C035-2-1, Nanjing Jiancheng, Nanjing, China). The mice were euthanized at the end of 14 weeks after administration, blood was collected from the heart, serum was centrifuged, and serum total cholesterol, creatinine, and urea nitrogen were examined by an automatic biochemical instrument (AU600, Olympus).

Pathomorphological observation of renal pathology

Mouse kidneys were fixed in 4% paraformaldehyde, dehydrated, paraffin-embedded, and made into sections (3 µm thick) for hematoxylin and eosin (H&E) (BA4025, Baso, Zhuhai, China) and periodic acid–Schiff (PAS) (BA4080A, Baso, China). Finally, the sections were sealed with glycerin gelatin (BA4348, Baso, China), and the results were observed under a microscope (DMI 8, Laica, Germany).

Ultrastructural changes under transmission electron microscope

Fresh intact renal cortex of 1 mm³ size was fixed in 2.5% glutaraldehyde, 4°C for 48 h, dehydrated by acetone

gradient, embedding, sectioning, lead citrate staining, uranyl acetate staining, sections were dried naturally and imaged and observed by transmission electron microscopy (HT7800).

Immunohistochemistry

Paraffin sections were dewaxed and hydrated, and thermal antigen repair was performed by antigen EDTA pH=9.0 (G1203, Servicebio, China) according to the primary antibody instructions, hydrogen peroxide for 10 min to eliminate endogenous peroxidase, blocking, corresponding primary antibodies nephrin (1:1500, ab216341, Abcam), NPHS2 (1:2000, ab181143, Abcam), GLP-1R (1:250, ab218532, Abcam), overnight at 4°C, HRP-labeled goat anti-rabbit secondary antibody immunoglobulin G (IgG) (1:50, A0208, Beyotime, Shanghai, China) was incubated at room temperature for 1 h, DAB color (ZLI-9018, Zsbio, Beijing, China) development for 10 min, and hematoxylin for 10 s, followed by dehydration, transparency, blocking, and microscopic examination.

Immunofluorescence

Paraffin sections were dewaxed and hydrated, antigen repaired, exposed to hydrogen peroxide for 10 min, blocked, and incubated with corresponding primary antibodies against nephrin (1:500), GLP-1R (1:250), IL-1 β (1:200), and NLRP3 (1:200) overnight at 4°C, FITC/CY3-labeled fluorescent secondary antibody (1:200) for 1 h. DAPI (MAO128, Meilunbio, China) stained nuclei for 5 min, the anti-fluorescence quencher was blocked, and the fluorescence microscopy images were captured.

Western blot

Mouse kidney tissues were lysed in the lysis solution containing RIPA and PMSF, ground in a tissue grinder, and then placed on ice for 30 min to obtain total protein. The supernatant was centrifuged and the protein concentration was determined by a BCA kit. The boiled 20–40 μ g of total protein were separated by gel electrophoresis, transferred, and blocked, followed by the addition of corresponding primary antibodies nephrin (1:1000, ab216341, Abcam), NPHS2 (1:2500, ab181143, Abcam), IL-1 β (1:1000, 12242, CST, USA), GSDMD (1:1000, 39754, CST, Danvers, MA, USA), cleaved GSDMD (1:1000, 10137, CST, USA), caspase-1 (1:1000, 24232, CST, USA), cleaved caspase-1 (1:1000, 89332, CST,

USA), internal reference GAPDH (1:5000, 10494-1-AP, Proteintech, China), and β -actin (1:3000, 20536-1-AP, Proteintech, China) overnight at 4°C in a shaking bed; 40 μ g of total protein cooked at 70°C were separated by gel electrophoresis, transferred to a membrane and blocked, followed by the addition of a primary antibody GLP-1R (1:1000, ab218532, Abcam) and an internal reference GAPDH (1:5000) overnight at 4°C in a shaking bed. After washing, the secondary antibody (1:3000) was added and incubated in a shaker at room temperature, and after washing, ECL luminescence solution was added dropwise and exposed to a chemiluminescence imager for photography. The expression of the target proteins was analyzed by ImageJ software for comparison.

Statistical analysis

All data are presented as the mean \pm s.e.m. Multiple group comparisons were assessed using one-way ANOVA. Statistical analyses were performed using GraphPad Prism 8.0 software. $P < 0.05$ was considered statistically significant.

Results

High-fat diet induces insulin resistance

After 4 weeks of different feedings, compared with the NC group, the mice in HFD group showed significantly higher blood glucose levels at 0 min, 30 min, 60 min, 90 min, and 120 min after intraperitoneal injection of glucose (all $P < 0.001$) (Fig. 1A). The area under the glucose curve AUC




Figure 1
(A) IPGTT experiment result. (B) AUC. **** $P < 0.0001$ vs NC.

in the HFD group was significantly increased compared with that in the NC group ($P < 0.0001$) (Fig. 1B). It indicated that the HFD induced insulin resistance successfully in the HFD group of mice.

Liraglutide improves urinary protein in DN mice

Compared with the NC group, the weight of mice in the DN group decreased at week 8 and week 14 after drug administration, which was consistent with the weight loss in type 2 diabetes models (T2DM) ($P < 0.05$). Compared with the DN+RI group, the body weight of the DN+Lira group decreased ($P < 0.0001$), indicating that liraglutide had a weight-reducing effect (Fig. 2A). Compared with the NC group, fasting blood glucose and 24-h urinary volume in the DN group were significantly increased at week 8 and week 14 after drug administration

(both $P < 0.0001$), which was consistent with the characteristics of polyuria and hyperglycemia T2DM. But compared with the DN group, the above indexes were significantly decreased in the DN+Lira group (both $P < 0.0001$) (Fig. 2B and C). This suggests that both liraglutide and degludec insulin can improve hypermetabolic state and lower blood glucose. Compared with the NC group, the 24-h urinary protein in the DN and DN+RI groups was significantly increased at week 8 and week 14 after drug administration (both $P < 0.0001$). The presence of proteinuria suggests progression to DN, and the treatment with degludec fails to reduce urinary protein. Compared with the DN and DN+RI groups, the urinary protein in the DN+Lira group was decreased (both $P < 0.05$) (Fig. 2D). It suggests that liraglutide is more effective than degludec in reducing urinary




Figure 2

Physiological and biochemical index results of each group of mice: (A) body weight; (B) fasting blood glucose; (C) 24-h urine volume; (D) 24-h urinary protein; (E) total cholesterol; (F) kidney weight/body ratio; (G) serum urea nitrogen; and (H) serum creatinine. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ vs NC; # $P < 0.05$, ## $P < 0.01$, ### $P < 0.001$, #### $P < 0.0001$ vs DN + Lira.

protein in the progression of DN.3.3. Liraglutide lowers total cholesterol in DN mice.

At week 14 after drug administration, total cholesterol (TC) was elevated in the DN and DN+RI groups compared with the NC group, consistent with the manifestation of hyperlipidemia in T2DM (both $P < 0.01$); total cholesterol (TC) was decreased in the DN+Lira group compared with the DN and DN+RI groups (both $P < 0.01$) (Fig. 2E). It shows that liraglutide has a hypolipidemic effect compared to degludec. The differences in serum creatinine (Scr), urea nitrogen (BUN), and the renal weight/body weight ratio were not statistically significant in each group of mice (Fig. 2F, G, and H).

Liraglutide attenuates pathological renal injury in DN mice

H&E staining and PAS staining showed that the glomerular thylakoid stroma was hyperplastic, and the glomerular volume was increased in the DN and DN+RI groups compared with the NC group; the above pathological changes were reduced in the DN+Lira group compared with the DN and DN+RI groups. The results of transmission electron microscopy showed that the mice in the DN and DN+RI groups showed a large fusion of podocyte peduncles, reduced number of peduncles, and thickening of glomerular basement membrane compared with the NC group; the mice in the DN+Lira group showed significantly improved fusion of

podocyte peduncles, reduced number of peduncles, and thickening of glomerular basement membrane compared with the DN and DN+RI groups (Fig. 3A, B, and C). This suggests that treatment with liraglutide is more effective in delaying renal pathology compared to degludec insulin.

Liraglutide attenuates podocyte damage in DN mice

Immunohistochemical staining and semiquantitative analysis showed that the expression of podocyte marker proteins NPHS2 and nephrin decreased in the kidneys of DN and DN+RI mice compared with the NC group (both $P < 0.0001$); the expression of NPHS2 and nephrin increased in the DN+Lira group compared with the DN and DN+RI groups (both $P < 0.0001$) (Fig. 4A and B). Western blot results of NPHS2 and nephrin protein and immunofluorescence staining and semiquantitative analysis of nephrin protein showed the same trend (all $P < 0.05$) (Fig. 4C and D). NPHS2 and nephrin protein expression levels decreased in both the DN and DN+RI groups, indicating that the number and function of podocytes were decreased in T2DM and that insulin hypoglycemic intervention did not significantly improve podocyte damage. NPHS2 and nephrin protein increased in the DN+Lira group compared with both the DN and DN+RI groups, indicating that liraglutide treatment attenuated podocyte damage and had a protective effect on podocytes in T2DM. In contrast, no protection of podocytes was observed with degludec insulin treatment.




Figure 3

Renal pathological injury in each group of mice: (A) H&E staining of mouse kidney tissues; (B) PAS staining of mouse kidney tissues; and (C) transmission microscopic observation of basement membrane thickness and pedicle width in mouse kidney cortex.




Figure 4 Liraglutide attenuates podocyte injury in each group of mice. (A) Immunohistochemical observation and semi-quantitative analysis of mouse glomerular NPHS2 protein expression. (B) Immunohistochemical observation and semi-quantitative analysis of mouse glomerular nephrin protein expression. (C) Immunofluorescence observation and semi-quantitative analysis of mouse glomerular nephrin protein expression. (D) Western blot semi-quantitative analysis of the protein expression levels of NPHS2 and nephrin in mouse kidneys. * $P < 0.05$, **** $P < 0.0001$ vs NC; ## $P < 0.01$, #### $P < 0.001$, ##### $P < 0.0001$ vs DN + Lira.

Liraglutide restores the reduced GLP-1R protein in the kidneys of DN mice

Immunohistochemical results showed that GLP-1R could be expressed in the glomerular and renal tubular epithelium (Fig. 5A). Immunofluorescence staining and semi-quantitative analysis showed that the expression of GLP-1R protein in the kidney decreased in the DN and DN+RI groups compared with the NC group (both $P < 0.0001$) and increased in the DN+Lira group compared with the DN and DN+RI groups (both $P < 0.0001$) (Fig. 5B). Western blot results also showed the same trend as immunofluorescence (all $P < 0.05$) (Fig. 5C).

In the DN and DN+RI groups, we observed a decreasing trend in renal GLP-1R protein expression

compared with the NC group, which verified that there was a reduction in renal GLP-1R protein expression in the T2DM mouse model. The hypoglycemic effect of Degu insulin does not reverse this change. In this experiment, we also found that liraglutide binds to GLP-1R expressed in renal tissues, and the level of GLP-1R protein expression in the kidneys of mice was significantly restored after its treatment.

Liraglutide ameliorates renal injury through NLRP3-mediated inflammation and pyroptosis

Immunofluorescence staining and semi-quantitative analysis showed that the expression of NLRP3 and IL-1 β proteins in the kidneys of mice in the DN and DN+RI




Figure 5

Changes in the expression site and amount of GLP-1R in the kidney of each group of mice. (A) Immunohistochemical method to observe the expression of GLP-1R protein in mouse glomeruli. (B) Immunofluorescence was used to observe and semi-quantitatively analyze the expression of GLP-1R protein in mouse kidney. (C) Western blot semi-quantitative analyses of the expression level of GLP-1R protein in mouse kidneys. *** $P < 0.001$, **** $P < 0.0001$ vs NC; # $P < 0.05$, ## $P < 0.01$, ### $P < 0.0001$ vs DN + Lira.

groups was significantly increased compared with that in the NC group (all $P < 0.01$). The expression of NLRP3 and IL-1 β proteins in the kidneys of mice in the DN+Lira group was significantly decreased compared with that in the DN and DN+RI groups (both $P < 0.01$) (Fig. 6A and B). The western blot results of IL-1 β , cleaved caspase-1, and cleaved GSDMD proteins showed the same trend (both $P < 0.001$) (Fig. 6C, D, and E).

The expression levels of NLRP3, IL-1 β , cleaved GSDMD, and cleaved caspase-1 proteins were increased in the DN and DN+RI groups, indicating that inflammation and pyroptosis were accompanied by the process of kidney injury in T2DM. The hypoglycemic effect of degludec insulin did not ameliorate these changes. The above indexes were decreased in the DN+Lira group compared with the DN and DN+RI groups, indicating that liraglutide reduced renal inflammation and pyroptosis in T2DM and had a protective effect on the kidney.

Discussion

In recent years, the treatment of diabetic nephropathy has focused on glycemic control and blood pressure management, but these measures have had little impact on the decrease in glomerular filtration rate and progression to ESRD (19). Liraglutide is a glucose-lowering agent approved for clinical use (20) and has received much attention in recent years for its protective effects in addition to its role in glycemic control (21). Several studies have shown that GLP-1RA attenuates proteinuria and delays the progression of renal injury in DN patients (22, 23). In the present study, by comparing the renal pathologic findings in mice from different administration treatment groups, we confirmed that liraglutide is effective in reducing kidney injury in the treatment of type 2 diabetic nephropathy compared to the pure hypoglycemic effect of insulin.




Figure 6

Expression of kidney inflammation and pyroptosis proteins in each group of mice. (A) Immunofluorescence observation and semiquantitative analysis of the expression level of mouse kidney NLRP3 protein. (B) Immunofluorescence observation and semiquantitative analysis of mouse kidney IL-1β protein expression. (C) Western blot semiquantitative analysis of mouse kidney caspase-1/cleaved caspase-1 protein expression. (D) Western blot semiquantitative analysis of mouse kidney GSDMD/cleaved GSDMD protein expression. (E) Western blot semiquantitative analysis of kidney IL-1β protein expression in mice. ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$ vs NC; ## $P < 0.01$, #### $P < 0.001$, ##### $P < 0.0001$ vs DN + Lira.

In the progression of DN, damage to podocytes is closely associated with proteinuria (24, 25). In the present experiment, we observed that liraglutide reduced proteinuria in DN mice, and combined with the transmission electron microscopy results of significantly improved pedicle fusion in DN+Lira group mice, we speculated that the protective effect of liraglutide on podocytes was one of the main mechanisms for its renal protective effect. In this study, we further detected the expression levels of kidney podocyte-specific proteins (NPHS2 and nephrin) in each group by immunohistochemistry, immunofluorescence

and Western blotting, and the results showed that the expression levels of NPHS2 protein and nephrin protein in DN+Lira group mice were increased compared with those in the DN group and DN+RI group, which verified the protective effect of liraglutide on DN mouse podocytes. This is consistent with the findings of previous study. This is consistent with the findings of previous studies (25, 26, 27). The same conclusion was reached in experiments related to mouse podocytes cultured in vitro (28). Because no improvement in renal injury was observed in the DN+RI group in this trial, we speculate that the renal protective effect of liraglutide

is not related to its hypoglycemic effect or that there are additional multiple mechanisms of protection.

GLP-1R agonists exert protective effects on the kidney through various molecular mechanisms such as endothelial protection and antifibrosis (29). In an obesity-associated glomerular disease model, GLP-1 also exerts a protective effect on the kidney by promoting the translocation of Glut4 to the cell membrane and inhibiting cellular autophagy, thereby attenuating podocyte injury (30). While whether GLP-1R plays a role in the protection of renal podocytes by liraglutide has not been clearly verified (25, 29, 31). Given that the main acting receptor of liraglutide is GLP-1R and it can be expressed in the kidney, whether GLP-1R plays a role in the protection of renal podocytes by liraglutide is still a question worth exploring. In the present experiment, we observed the expression of GLP-1R protein in the kidney of each group of mice by immunohistochemistry and immunofluorescence staining and found that both glomerular podocytes and renal tubular epithelium of mice could express GLP-1R, which further improved the previous study (31, 32, 33). Therefore, we further speculated that the protective effect of liraglutide on podocytes might be related to the renal expression of GLP-1R. To further verify the above speculation, we analyzed the expression level of GLP-1R protein in mouse kidney tissues by immunofluorescence semiquantitative and western blot semiquantitative analysis. The experimental results all showed that the expression level of GLP-1R protein in renal tissues of mice in the DN group and DN+RI group was reduced compared with that of mice in the normal control group, while the expression level of GLP-1R protein in renal tissues was significantly restored after liraglutide treatment. Through this experiment, we found that the expression of GLP-1R protein in renal tissues was reduced by the DN environment, suggesting that the reduction of GLP-1R protein may be one of the mechanisms of action of renal injury in T2DM. And liraglutide can bind to GLP-1R expressed in renal tissues in DN and ameliorate this adverse effect of GLP-1R by the DN environment. Since we observed less GLP-1R protein expressed by podocytes in immunohistochemical staining results, we suggest that the protective effect of liraglutide on podocytes may be partly dependent on changes in GLP-1R expressed by podocytes, and there may also be a non-GLP-1R-dependent protective mechanism.

DN is considered an inflammatory disease, and several studies have shown that activation of

inflammatory vesicles (NLRP3) and their mediated cellular scorching can promote the development of multiple complications of diabetes, including DN and diabetic neuropathy (34, 35, 36). NLRP3 induces cellular scorching, a specific form of inflammation-driven apoptosis (37). Activation of NLRP3 is observed in mouse models of diabetic nephropathy and in podocytes after angiotensin-II-aldosterone stimulation, and in these models, blockade of the pharmacological mechanism of NLRP3 ameliorates albuminuria and podocyte injury (38, 39, 40). Meanwhile, it has been demonstrated that podocyte injury also activates the NLRP3-ASC-caspase-1 axis, releasing mature IL-1 β and IL-1 (41, 42, 43), and activates pro-caspase-1, which cleaves to activated caspase-1 (44) and cleaves GSDMD to GSDMD-C and GSDMD-N (i.e. cleaved-GSDMD in this paper) (45, 46), further causing cellular scorching (47) and accelerating the progression of DN. Therefore, we speculate that the protective effect of liraglutide on podocytes in the treatment of diabetic nephropathy may be related to the improvement of renal inflammation and cellular scorching. To verify this conjecture, this experiment further detected the expression of inflammation and cell scorching-related proteins in the kidney tissue of DN mice by Western blot and immunofluorescence assays, and the results showed that inflammation and cell scorching in the kidneys of mice were significantly improved after liraglutide treatment. On contrast, this phenomenon was not observed in the degludec insulin-treated group. This indicates that liraglutide can improve podocyte injury in diabetic nephropathy by regulating NLRP3-mediated cell scorching.

In this study, due to the lack of kidney biopsy samples from patients with diabetic nephropathy who only used liraglutide intervention, the conclusions of this experiment lack clinical data support, and clinical samples need to be collected at a later stage to further investigate the role of liraglutide in the damage of podocytes in diabetic nephropathy. In addition, whether the protective effect of liraglutide on podocytes is mediated through GLP-1R needs to be further verified by animal GLP-1R knockout models.

In conclusion, liraglutide can protect podocytes by regulating renal inflammation and cellular scorching, thereby reducing glomerular injury in diabetic nephropathy mice, decreasing proteinuria production, and delaying the progression of diabetic nephropathy to end-stage renal disease. This protective effect may be partly related to GLP-1R expressed by podocytes.

Declaration of interest

The authors declare no conflict of interest.

Funding

This work was supported by Jingzhou Science and Technology Project (2022HC46), Innovation Fund Project of Yangtze University of Medical Department (202206).

Author contribution statement

TM conceived the project; SS and XC designed the experiments; SS performed all experiments, data collection, and data analysis; WY and XK prepared the reagents and collected the samples; TM and XC supervised the study; SS and XC wrote the manuscript.

References

- Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Mbanya JC, *et al.* IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. *Diabetes Research and Clinical Practice* 2022 **183** 109119. (<https://doi.org/10.1016/j.diabres.2021.109119>)
- Dong R, Yu JL, Yu FX, Yang S, Qian Q & Zha Y. IGF-1/IGF-1R blockade ameliorates diabetic kidney disease through normalizing Snail 1 expression in a mouse model. *American Journal of Physiology-Endocrinology and Metabolism* 2019 **317** E686–E698. (<https://doi.org/10.1152/ajpendo.00071.2019>)
- Barutta F, Bellini S & Gruden G. Mechanisms of podocyte injury and implications for diabetic nephropathy. *Clinical Science* 2022 **136** 493–520. (<https://doi.org/10.1042/CS20210625>)
- Scott RP & Quaggin SE. Review series: the cell biology of renal filtration. *Journal of Cell Biology* 2015 **209** 199–210. (<https://doi.org/10.1083/jcb.201410017>)
- Garg P. A review of podocyte biology. *American Journal of Nephrology* 2018 **47**(Supplement 1) 3–13. (<https://doi.org/10.1159/000481633>)
- Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P & Susztak K. Molecular pathways that drive diabetic kidney disease. *Journal of Clinical Investigation* 2023 **133**. (<https://doi.org/10.1172/JCI165654>)
- Meyer TW, Bennett PH & Nelson RG. Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria. *Diabetologia* 1999 **42** 1341–1344. (<https://doi.org/10.1007/s001250051447>)
- Li J, Zheng S, Ma C, Chen X, Li X, Li S, Wang P, Chen P, Wang Z, Li W, *et al.* Research progress on exosomes in podocyte injury associated with diabetic kidney disease. *Frontiers in Endocrinology* 2023 **14** 1129884. (<https://doi.org/10.3389/fendo.2023.1129884>)
- Mukhi D & Susztak K. The transcriptomic signature of the aging podocyte. *Kidney International* 2020 **98** 1079–1081. (<https://doi.org/10.1016/j.kint.2020.08.004>)
- Du P, Fan B, Han H, Zhen J, Shang J, Wang X, Li X, Shi W, Tang W, Bao C, *et al.* NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resistance in diabetic nephropathy. *Kidney International* 2013 **84** 265–276. (<https://doi.org/10.1038/ki.2013.113>)
- Niu J, Min W, Ai J, Lin X, Miao J, Zhou S, Liang Y, Chen S, Ren Q, *et al.* B7-1 mediates podocyte injury and glomerulosclerosis through communication with Hsp90ab1-LRP5- β -catenin pathway. *Cell Death and Differentiation* 2022 **29** 2399–2416. (<https://doi.org/10.1038/s41418-022-01026-8>)
- Muskiet MHA, Smits MM, Morsink LM & Diamant M. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes? *Nature Reviews. Nephrology* 2014 **10** 88–103. (<https://doi.org/10.1038/nrneph.2013.272>)
- Korner M, Stockli M, Waser B & Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. *Journal of Nuclear Medicine* 2007 **48** 736–743. (<https://doi.org/10.2967/jnumed.106.038679>)
- Kim SJ, Kwon SK, Kim HY, Kim SM, Bae JW & Choi JK. DPP-4 inhibition enhanced renal tubular and myocardial GLP-1 receptor expression decreased in CKD with myocardial infarction. *BMC Nephrology* 2019 **20** 75. (<https://doi.org/10.1186/s12882-019-1243-z>)
- Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, *et al.* Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. *Diabetologia* 2011 **54** 965–978. (<https://doi.org/10.1007/s00125-010-2028-x>)
- Yang Q, Lang Y, Yang W, Yang F, Yang J, Wu Y, Xiao X, Qin C, Zou Y, Zhao Y, *et al.* Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. *Diabetes Research and Clinical Practice* 2023 **198** 110592. (<https://doi.org/10.1016/j.diabres.2023.110592>)
- Moellmann J, Klinkhammer BM, Onstein J, Stohr R, Jankowski V, Jankowski J, Lebherz C, Tacke F, Marx N, Boor P, *et al.* Glucagon-like peptide 1 and its cleavage products are renoprotective in murine diabetic nephropathy. *Diabetes* 2018 **67** 2410–2419. (<https://doi.org/10.2337/db17-1212>)
- Li D, Jiang C, Mei G, Zhao Y, Chen L, Liu J, Tang Y, Gao C & Yao P. Quercetin Alleviates Ferroptosis of Pancreatic beta Cells in Type 2 Diabetes. *Nutrients* 2020 **12**. (<https://doi.org/10.3390/nu12102954>)
- Forst T, Mathieu C, Giorgino F, Wheeler DC, Papanas N, Schmieler RE, Halabi A, Schnell O, Streckbein M & Tuttle KR. New strategies to improve clinical outcomes for diabetic kidney disease. *BMC Medicine* 2022 **20** 337. (<https://doi.org/10.1186/s12916-022-02539-2>)
- Burcelin R & Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. *Obesity Reviews* 2017 **18** 86–98. (<https://doi.org/10.1111/obr.12465>)
- Bendotti G, Montefusco L, Lunati ME, Usueli V, Pastore I, Lazzaroni E, Assi E, Seelam AJ, El Essawy B, Jang J, *et al.* The anti-inflammatory and immunological properties of GLP-1 Receptor agonists. *Pharmacological Research* 2022 **182** 106320. (<https://doi.org/10.1016/j.phrs.2022.106320>)
- Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, *et al.* Cardiovascular and renal outcomes with Efgpeglatide in Type 2 diabetes. *New England Journal of Medicine* 2021 **385** 896–907. (<https://doi.org/10.1056/NEJMoa2108269>)
- Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB & Botros FT. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. *Lancet. Diabetes and Endocrinology* 2018 **6** 605–617. ([https://doi.org/10.1016/S2213-8587\(18\)30104-9](https://doi.org/10.1016/S2213-8587(18)30104-9))
- Kravets I & Mallipattu SK. The role of podocytes and podocyte-associated biomarkers in diagnosis and treatment of diabetic kidney disease. *Journal of the Endocrine Society* 2020 **4** bvaa029. (<https://doi.org/10.1210/jendso/bvaa029>)
- Dalbøge L, Christensen M, Madsen M, Secher T, Endlich N, Drenic V, Manresa-Arraut A, Hansen H, Rune I, Fink L, *et al.* Nephroprotective effects of semaglutide as mono- and combination treatment with Lisinopril in a mouse model of hypertension-accelerated diabetic kidney disease. *Biomedicine* 2022 **10** 1661. (<https://doi.org/10.3390/biomedicine10071661>)

- 26 Wang J, Zhou Y, Long D, Wu Y & Liu F. GLP-1 receptor agonist, liraglutide, protects podocytes from apoptosis in diabetic nephropathy by promoting white fat browning. *Biochemical and Biophysical Research Communications* 2023 **664** 142–151. (<https://doi.org/10.1016/j.bbrc.2023.04.012>)
- 27 Ye Y, Zhong X, Li N & Pan T. Protective effects of liraglutide on glomerular podocytes in obese mice by inhibiting the inflammatory factor TNF- α -mediated NF- κ B and MAPK pathway. *Obesity Research and Clinical Practice* 2019 **13** 385–390. (<https://doi.org/10.1016/j.orcp.2019.03.003>)
- 28 Shi JX & Huang Q. Glucagonlike peptide 1 protects mouse podocytes against high glucose-induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro. *Molecular Medicine Reports* 2018 **18** 1789–1797. (<https://doi.org/10.3892/mmr.2018.9085>)
- 29 Yaribeygi H, Atkin SL, Montecucco F, Jamialahmadi T & Sahebkar A. Renoprotective effects of incretin-based therapy in diabetes mellitus. *BioMed Research International* 2021 **2021** 8163153. (<https://doi.org/10.1155/2021/8163153>)
- 30 Guo H, Wang B, Li H, Ling L, Niu J & Gu Y. Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes. *American Journal of Physiology. Renal Physiology* 2018 **314** F181–F189. (<https://doi.org/10.1152/ajprenal.00302.2017>)
- 31 Barrera-Chimal J & Jaissier F. Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets. *Diabetes, Obesity and Metabolism* 2020 **22**(Supplement 1) 16–31. (<https://doi.org/10.1111/dom.13969>)
- 32 Choi JH, Kim SJ, Kwon SK, Kim HY & Jeon H. Renal tubular glucagon-like Peptide-1 receptor expression is increased in early sepsis but reduced in chronic kidney disease and sepsis-induced kidney injury. *International Journal of Molecular Sciences* 2019 **20**. (<https://doi.org/10.3390/ijms20236024>)
- 33 Nistala R, Habibi J, Aroor A, Sowers JR, Hayden MR, Meuth A, Knight W, Hancock T, Klein T, DeMarco VG, *et al.* DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the Zucker obese rat. *Obesity* 2014 **22** 2172–2179. (<https://doi.org/10.1002/oby.20833>)
- 34 Ding H, Li J, Li Y, Yang M, Nie S, Zhou M, Zhou Z, Yang X, Liu Y & Hou FF. MicroRNA-10 negatively regulates inflammation in diabetic kidney via targeting activation of the NLRP3 inflammasome. *Molecular Therapy* 2021 **29** 2308–2320. (<https://doi.org/10.1016/j.ymthe.2021.03.012>)
- 35 Al Mamun A, Ara Mimi A, Wu Y, Zaeem M, Abdul Aziz M, Aktar SS, Alyafeai E, Munir F & Xiao J. Pyroptosis in diabetic nephropathy. *Clinica Chimica Acta* 2021 **523** 131–143. (<https://doi.org/10.1016/j.cca.2021.09.003>)
- 36 Zheng S, Zhang K, Zhang Y, He J, Ouyang Y, Lang R, Ao C, Jiang Y, Xiao H, Li Y, *et al.* Human umbilical cord mesenchymal stem cells inhibit pyroptosis of renal tubular epithelial cells through miR-342-3p/Caspase1 signaling pathway in diabetic nephropathy. *Stem Cells International* 2023 **2023** 5584894. (<https://doi.org/10.1155/2023/5584894>)
- 37 Liu P, Zhang ZD & Li Y. Relevance of the pyroptosis-related inflammasome pathway in the pathogenesis of diabetic kidney disease. *Frontiers in Immunology* 2021 **12** 603416. (<https://doi.org/10.3389/fimmu.2021.603416>)
- 38 Zhao M, Bai M, Ding GX, Zhang Y, Huang SM, Jia ZJ & Zhang AH. Angiotensin II stimulates the NLRP3 inflammasome to induce podocyte injury and mitochondrial dysfunction. *Kidney Diseases* 2018 **4** 83–94. (<https://doi.org/10.1159/000488242>)
- 39 Jiang MZ, Zhao M, Bai M, Lei J, Yuan YG, Huang SM, Zhang Y, Ding GX, Jia ZJ & Zhang AH. SIRT1 alleviates aldosterone-induced podocyte injury by suppressing mitochondrial dysfunction and NLRP3 inflammasome activation. *Kidney Diseases* 2021 **7** 293–305. (<https://doi.org/10.1159/000513884>)
- 40 Shahzad K, Fatima S, Khawaja H, Elwakiel A, Gadi I, Ambreen S, Zimmermann S, Mertens PR, Biemann R & Isermann B. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease. *Kidney International* 2022 **102** 766–779. (<https://doi.org/10.1016/j.kint.2022.06.010>)
- 41 Komada T & Muruve DA. The role of inflammasomes in kidney disease. *Nature Reviews. Nephrology* 2019 **15** 501–520. (<https://doi.org/10.1038/s41581-019-0158-z>)
- 42 Swanson KV, Deng M & Ting JPY. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nature Reviews. Immunology* 2019 **19** 477–489. (<https://doi.org/10.1038/s41577-019-0165-0>)
- 43 Xu J & Nunez G. The NLRP3 inflammasome: activation and regulation. *Trends in Biochemical Sciences* 2023 **48** 331–344. (<https://doi.org/10.1016/j.tibs.2022.10.002>)
- 44 Chen X, He WT, Hu LC, Li JX, Fang Y, Wang X, Xu XZ, Wang Z, Huang K & Han JH. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. *Cell Research* 2016 **26** 1007–1020. (<https://doi.org/10.1038/cr.2016.100>)
- 45 Fu JN & Wu H. Structural mechanisms of NLRP3 inflammasome assembly and activation. *Annual Review of Immunology* 2023 **41** 301–316. (<https://doi.org/10.1146/annurev-immunol-081022-021207>)
- 46 Burdette BE, Esparza AN, Zhu H & Wang S. Gasdermin D in pyroptosis. *Acta Pharmaceutica Sinica. B* 2021 **11** 2768–2782. (<https://doi.org/10.1016/j.apsb.2021.02.006>)
- 47 Li W, Sun J, Zhou X, Lu Y, Cui W & Miao L. Mini-review: GSDME-mediated pyroptosis in diabetic nephropathy. *Frontiers in Pharmacology* 2021 **12** 780790. (<https://doi.org/10.3389/fphar.2021.780790>)

Received 13 July 2023

Accepted 31 July 2023

Available online 31 July 2023

Version of Record published 28 August 2023